Observational studyEpidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil2025
Variability in public procurement prices for Group 1A drugs in the specialized pharmaceutical component: an observational study, 2013-2022.
Observational study in Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the difference in acquisition prices of Group 1A drugs in the Specialized Pharmaceutical Component between purchases made by the Brazilian Ministry of Health and those made by the Paraná State Health Department.
methodsThis was a retrospective observational study comparing prices of medications acquired centrally by the Brazilian Ministry of Health and those acquired by the State of Paraná to meet court orders or to supply supplementary lists, from 2013 to 2022. The weighted average acquisition price was calculated for each procurement source, per year, based on data from the Paraná Health Department management information system. The ratio between Paraná's and the Brazilian Ministry of Health's weighted average prices was calculated, as well as the hypothetical cost of Paraná's purchases had they been made at the Ministry's prices. Total overpricing in Paraná's acquisitions was also calculated.
resultsA total of 500 price comparisons were conducted, covering 116 different drug presentations. In 84.6% of the comparisons, Paraná's prices exceeded those of the Ministry of Health. For seven pharmaceutical presentations, the state price was more than 10 times higher than the federal price, reaching as high as 47.32 times in the most extreme case. Overall, Paraná's expenditures exceeded by more than BRL 200 million the amount that would have been paid at the Ministry's prices, resulting in 55.7% overpricing.
conclusionThere was considerable variation between prices of drugs acquired centrally by the Brazilian Ministry of Health and those acquired by the state of Paraná. To enhance cost-effectiveness within the Brazilian National Health System, mechanisms for centralized price negotiation or procurement should be further explored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.